Spots Global Cancer Trial Database for A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Official Title: A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)
Study ID: NCT02431208
Conditions
Study Description
Brief Summary: This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
University Of Arkansas, Little Rock, Arkansas, United States
Scripps Clinic Torrey Pines, La Jolla, California, United States
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
University of California, San Francisco, San Francisco, California, United States
Yale University, New Haven, Connecticut, United States
Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States
Loyola University Med Center, Maywood, Illinois, United States
Indiana University Health; Goshen Center for Cancer Care, Goshen, Indiana, United States
Indiana University Department of Medicine; IU Simon Cancer Center, Indianapolis, Indiana, United States
University of Louisville, Louisville, Kentucky, United States
University of Maryland School of Medicine, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Med Ctr; Hem/Onc, Boston, Massachusetts, United States
Univ of Michigan Medical Ctr, Ann Arbor, Michigan, United States
Karmanos Cancer Institute., Detroit, Michigan, United States
Henry Ford Hospital; Hematology Oncology, Detroit, Michigan, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States
Mount SInai Medical Center, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
University of Oklahoma Health Sciences Center; Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Lifespan Cancer Institute, Providence, Rhode Island, United States
Medical University of South Carolina; Hollings Cancer Center, Charleston, South Carolina, United States
Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
UT Southwestern MC at Dallas, Dallas, Texas, United States
Houston Methodist Cancer Center, Houston, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Contact Details
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
